Physician profile

Alexandra Kretowicz

Lone Tree, CO

NPI 1023390150

$1,392.61

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$973.47

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $443.59 2023
Galderma Laboratories, L.P. $332.33 2020-2023 Twyneo, Aklief, Oracea
Allergan, INC. $178.38 2021-2022
Genzyme Corporation $143.32 2023
Novo Nordisk INC $140.37 2023 Wegovy
Regeneron Healthcare Solutions, INC. $71.80 2023 Dupixent
Amgen INC. $36.59 2023 Otezla
Mayne Pharma Commercial LLC $23.66 2023
Pfizer INC. $22.57 2023

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Alexandra Kretowicz

$1,392.61

in general payments reported 2019-2025

Years
2020-2023
Top company
Abbvie INC.

https://glasscript.com/doctor/8803348/alexandra-kretowicz

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.